Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 9:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 4,637 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Be Specific Clear all
Completed Phase 1 Interventional

Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE)

NCT02973113
View directory record Official record
Conditions
NonHodgkin Lymphoma, Lymphoproliferative Disorders, EBV Related Lymphoma, EBV-Related PTLD, Hodgkin Lymphoma, EBV Related Non-Hodgkin's Lymphoma, EBV Related Hodgkin's Lymphoma
Interventions
EBVST Cells, Nivolumab
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 21, 2021 · Synced Oct 23, 2026, 9:54 PM EDT
Completed Phase 2 Interventional Results available

Redirected Auto T Cells for Advanced Myeloma

NCT01352286
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Autologous Genetically modified T cells
Genetic
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
2
States / cities
Baltimore, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced Oct 23, 2026, 9:54 PM EDT
Completed Phase 1 Interventional

Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma

NCT01421524
View directory record Official record
Conditions
Multiple Myeloma, Lymphoma, Large B-Cell, Diffuse, Pleiotropic Pathway Modifier, Glioblastoma, Lymphoma, Primary Central Nervous System Lymphoma
Interventions
CC-122
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2023
U.S. locations
17
States / cities
Duarte, California • Los Angeles, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Oct 23, 2026, 9:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986331 in Healthy Participants

NCT04444050
View directory record Official record
Conditions
Healthy Participants
Interventions
BMS-986331, Placebo, Matching BMS-986331
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Anaheim, California • Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 20, 2022 · Synced Oct 23, 2026, 9:54 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

FAmily CEntered (FACE) Advance Care Planning for Teens With Cancer

NCT01670461
View directory record Official record
Conditions
Cancer
Interventions
FACE, Standard of Care (SOC) Control
Behavioral
Lead sponsor
Maureen Lyon
Other
Eligibility
14 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 8, 2019 · Synced Oct 23, 2026, 9:54 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Non-Opioid Pain Medications After Intracapsular Adenotonsillectomy

NCT04791761
View directory record Official record
Conditions
Adenotonsillectomy, Post-operative Analgesia, Opioid Use
Interventions
Oxycodone, Ibuprofen, Acetaminophen, Opioid disposal pouch, Opioid disposal education
Drug · Other
Lead sponsor
David Chi, MD
Other
Eligibility
3 Years to 17 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 30, 2024 · Synced Oct 23, 2026, 9:54 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in Participants From Birth to 12 Months of Age With Hemophilia A Without Inhibitors

NCT04431726
View directory record Official record
Conditions
Severe Hemophilia A
Interventions
Emicizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
0 Months to 12 Months
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
6
States / cities
Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 23, 2026, 9:54 PM EDT
Recruiting Not applicable Interventional

Changes in Body Composition Including Muscle With Anti-Obesity Medications, Both With and Without Exercise

NCT07698145
View directory record Official record
Conditions
Obesity & Overweight
Interventions
Standard Medical Care with an Obesity Management Medication, Cardiovascular Exercise Training, Resistance Exercise Training, Nutrition Counseling
Other · Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 64 Years
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 23, 2026, 9:54 PM EDT
Completed Phase 4 Interventional Results available

The Safety/Efficacy of Rifaximin With/Without Lactulose in Participants With A History of Recurrent Hepatic Encephalopathy

NCT01842581
View directory record Official record
Conditions
Hepatic Encephalopathy, Cirrhosis
Interventions
Rifaximin, Lactulose
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
43
States / cities
Phoenix, Arizona • Coronado, California • Fresno, California + 35 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2019 · Synced Oct 23, 2026, 9:54 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)

NCT04596995
View directory record Official record
Conditions
Primary Immune Thrombocytopenia
Interventions
Rozanolixizumab
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 5, 2024 · Synced Oct 23, 2026, 9:54 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors

NCT06237881
View directory record Official record
Conditions
Advanced Solid Tumor, Melanoma, Lung Neoplasms, Head and Neck Neoplasms
Interventions
KSQ-001EX, Interleukin-2, Cyclophosphamide, Fludarabine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 23, 2026, 9:54 PM EDT
Recruiting Not applicable Interventional

REMIND Maintenance Radiotherapy for Newly Diagnosed Glioblastoma

NCT07831772
View directory record Official record
Conditions
Glioblastoma, Newly Diagnosed Glioblastoma, Brain Tumor
Interventions
Maintenance Radiotherapy
Radiation
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 23, 2026, 9:54 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Influence of Immersive Virtual Field Trips on Academic Vocabulary

NCT05242575
View directory record Official record
Conditions
Developmental Language Disorder, Language Disorders in Children
Interventions
The information provided in the iVFT and control book parallel one another.
Behavioral
Lead sponsor
Salus University
Other
Eligibility
6 Years to 8 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Elkins Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 12, 2023 · Synced Oct 23, 2026, 9:54 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)

NCT03992131
View directory record Official record
Conditions
Ovarian Cancer, Triple-negative Breast Cancer, Urothelial Carcinoma, Solid Tumor
Interventions
Rucaparib, Lucitanib, Sacituzumab govitecan
Drug
Lead sponsor
pharmaand GmbH
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
3
States / cities
Boston, Massachusetts • Nashville, Tennessee • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 16, 2024 · Synced Oct 23, 2026, 9:54 PM EDT
Completed Not applicable Interventional

Biomechanical and Neural Mechanisms of Post-stroke Gait Training

NCT04380454
View directory record Official record
Conditions
Stroke
Interventions
Functional electrical stimulation (FES), Fast treadmill walking
Device · Other
Lead sponsor
Emory University
Other
Eligibility
35 Years to 90 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 23, 2026, 9:54 PM EDT
Completed Not applicable Interventional

Dedicated Ambulator-assisted Physical Activity to Improve Hospital Outcome Measures in Elderly Patients

NCT02757131
View directory record Official record
Conditions
Weakness, Hospital Acquired Condition
Interventions
Ambulation
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
60 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 10, 2017 · Synced Oct 23, 2026, 9:54 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Characterization of the Melanoma-Specific Immune Response

NCT00368615
View directory record Official record
Conditions
Melanoma
Interventions
Not listed
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2024
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 23, 2024 · Synced Oct 23, 2026, 9:54 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Study of the Effect of a 5-Day Regimen of Study Drug on Peripheral Stem Cell Mobilization in Healthy Participants

NCT03029000
View directory record Official record
Conditions
Healthy Participants
Interventions
Tbo-filgrastim
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
9
States / cities
Duarte, California • La Jolla, California • Beech Grove, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2022 · Synced Oct 23, 2026, 9:54 PM EDT
Completed No phase listed Observational

A Study on Patients With Chronic Kidney Disease (CKD) to Assess Treatment Experience and Patterns, Effect of the Treatment, Patient Outcomes and Patient Quality of Life

NCT04034992
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Not listed
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
1,052 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
11
States / cities
Riverside, California • San Francisco, California • Sanford, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2024 · Synced Oct 23, 2026, 9:54 PM EDT
Completed Not applicable Interventional

Improving STEM Outcomes for Young Children With Language Learning Disabilities Via Telehealth

NCT04775199
View directory record Official record
Conditions
Language Development Disorders
Interventions
Language Intervention
Behavioral
Lead sponsor
Karla McGregor
Other
Eligibility
4 Years to 7 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 23, 2026, 9:54 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Impact of Physician Contact on Patient Anxiety During the Waiting Period After Embryo Transfer

NCT04190732
View directory record Official record
Conditions
Infertility
Interventions
Physician phone call
Behavioral
Lead sponsor
Boston IVF
Other
Eligibility
18 Years to 43 Years · Female only
Enrollment
231 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 11, 2022 · Synced Oct 23, 2026, 9:54 PM EDT
Completed Phase 4 Interventional Results available

A Real-World Evidence Study to Evaluate the Effects of Voltaren Use on Mobility and Quality of Life in Participants With Knee Osteoarthritis Pain

NCT06379893
View directory record Official record
Conditions
Pain
Interventions
Voltaren Gel
Drug
Lead sponsor
HALEON
Industry
Eligibility
40 Years to 85 Years
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
2
States / cities
Marrero, Louisiana • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 23, 2026, 9:54 PM EDT
Completed Phase 2 Interventional Results available

A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Arthritis

NCT01085084
View directory record Official record
Conditions
Lupus Arthritis
Interventions
Laquinimod, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2022 · Synced Oct 23, 2026, 9:54 PM EDT
Recruiting No phase listed Observational

fMRI and Opioid Abstinence

NCT06651333
View directory record Official record
Conditions
Drug Use Disorder, Opioid Dependence, Opioid-Related Disorders, Opioid Use, Opioid Abuse
Interventions
fMRI
Diagnostic Test
Lead sponsor
Yale University
Other
Eligibility
18 Years to 50 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
2
States / cities
Hartford, Connecticut • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 23, 2026, 9:54 PM EDT